Heterogeneous response to HAART across a diverse population of people living with HIV: Results from the ANRS-EN12-VESPA study

AIDS

Volumn 21, Issue SUPPL. 1, 2007, Pages

  Dray Spira, R ^a   Spire, Bruno ^a,c   Heard, Isabelle ^d   Lert, France ^a,b   Bouhnik, A D ^a   Fagnani, J ^f   Heard, I ^d   Lert, F ^a   Obadia, Y ^a   Peretti Watel, P ^a   Pierret, J ^a   Riandey, B ^g   Schiltz, M A ^a   Sitta, R ^a   Spire, B ^a  

^a INSERM   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e Hospital National de Saint Maurice   (France)

^f CNRS   (France)

^g INED   (France)

Author keywords

Cross sectional study; France; HAART; HIV infection; Migrants; Treatment failure

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BISEXUALITY; CD4 LYMPHOCYTE COUNT; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; FRANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 33845707456     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000255079.39352.9b     Document Type: Article

References (34)

1. Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362 (9385):679-686.
2. Moore DM, Hogg RS, Chan K, Tyndall M, Yip B, Montaner JS. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS 2006; 20:371-377.
3. Sabin CA, Smith CJ, Youle M, Lampe FC, Bell DR, Puradiredja D, et al. Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS 2006; 20 (1):67-71.
4. Sterne JA, Hernan MA, Ledergerber B, Tilling K, Weber R, Sendi P, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366 (9483):378-384.
5. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr 2004; 35:261-268.
6. Barron Y, Cole SR, Greenblatt RM, Cohen MH, Anastos K, DeHovitz JA, et al. Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy. AIDS 2004; 18 (11):1579-1584.
7. Viard JP, Mocroft A, Chiesi A, Kirk O, Roge B, Panos G, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001; 183 (8):1290-1294.
8. Giordano TP, Wright JA, Hasan MQ, White AC Jr, Graviss EA, Visnegarwala F. Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis 2003; 37:433-437.
9. Bouhnik AD, Preau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, et al. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther 2005; 10 (1):53-61.
10. Miller MF, Haley C, Koziel MJ, Rowley CF. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis 2005; 41:713-720.
11. Lucas GM, Griswold M, Gebo KA, Keruly J, Chaisson RE, Moore RD. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol 2006; 163:412-420.
12. Hamers FF, Downs AM. The changing face of the HIV epidemic in western Europe: what are the implications for public health policies? Lancet 2004; 364:83-94.
13. Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM. Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindigenous HIV-1-infected patients in the Netherlands. J Acquir Immune Defic Syndr 2004; 36:943-950.
14. Sabine C. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? AIDS 2005; 19:1995-2000.
15. Bourdillon F, Nadal J. Health problems and needs of HIV-infected persons: multicentric hospital survey [in French]. Ministère de l'Emploi et de la Solidarité, Direction des Hôpitaux - Mission Sida. Paris, 1996.
16. Peretti-Watel P, Riandey B, Dray-Spira R, Bouhnik AD, Sitta R, Obadia Y, et al. Surveying the HIV-Positive Population in France. The ANRS-EN12-VESPA 2003 Survey [in French]. Population 2005; 60 (4):525-550.
17. Deville JC, Särndal CE. Calibration estimation in survey sampling. J Am Stat Assoc 1992; 87:375-382.
18. Lert F, Obadia Y, and the ANRS-VESPA survey team. Living with HIV/AIDS in France [in French]. Population and societies. 2004;(406):1-5.
19. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67:361-370.
20. Carrieri MP, Raffi F, Lewden C, Sobel A, Michelet C, Cailleton V, et al. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir Ther 2003; 8 (6):585-594.
21. Peretti-Watel P, Spire B, Schiltz MA, Bouhnik AD, Heard I, Lert F, et al. Vulnerability, unsafe sex and non-adherence to HAART: evidence from a large sample of French HIV/AIDS outpatients. Soc Sci Med 2006; 62 (10):2420-2433.
22. Goldberg M, Chastang JF, Leclerc A, Zins M, Bonenfant S, Bugel I, et al. Socioeconomic, demographic, occupational, and health factors associatedwith participation in a long-term epidemiologic survey: a prospective study of the French GAZEL cohort and its target population. Am J Epidemiol 2001; 154 (4):373-384.
23. Jensen-Fangel S, Pedersen L, Pedersen C, Larsen CS, Tauris P, Moller A, et al. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis 2002; 35 (12):1541-1548.
24. Smith CJ, Sabin CA, Youle MS, Kinloch-de Loes S, Lampe FC, Madge S, et al. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis 2004; 190 (10):1860-1868.
25. Frater AJ, Dunn DT, Beardall AJ, Ariyoshi K, Clarke JR, McClure MO, et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002; 16 (8):1139-1146.
26. Anastos K, Schneider MF, Gange SJ, Minkoff H, Greenblatt RM, Feldman J, et al. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women. J Acquir Immune Defic Syndr 2005; 39 (5):537-544.
27. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367 (9513):817-824.
28. Jones DJ, Beach SR, Forehand R. Disease status in African American single mothers with HIV: the role of depressive symptoms. Health Psychol 2001; 20:417-423.
29. Smith MY, Rapkin BD, Winkel G, Springer C, Chhabra R, Feldman IS. Housing status and health care service utilization among low-income persons with HIV/AIDS. J Gen Intern Med 2000; 15:731-738.
30. Ashton E, Vosvick M, Chesney M, Gore-Felton C, Koopman C, O'Shea K, et al. Social support and maladaptive coping as predictors of the change in physical health symptoms among persons living with HIV/AIDS. AIDS Patient Care STDS 2005; 19 (9):587-598.
31. Ironson G, O'Cleirigh C, Fletcher MA, Laurenceau JP, Balbin E, Klimas N, et al. Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment. Psychosom Med 2005; 67 (6):1013-1021.
32. Kalichman SC, Catz S, Ramachandran B. Barriers to HIV/AIDS treatment and treatment adherence among African-American adults with disadvantaged education. J Natl Med Assoc 1999; 91:439-446.
33. Wolf MS, Davis TC, Arozullah A, Penn R, Arnold C, Sugar M, et al. Relation between literacy and HIV treatment knowledge among patients on HAART regimens. AIDS Care 2005; 17 (7):863-873.
34. Erwin J, Peters B. Treatment issues for HIV+ Africans in London. Soc Sci Med 1999; 49:1519-1528.